Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.30 |
| ▸ | TUBB | P07437 | 2/20 | 0.30 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.30 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.30 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.30 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.30 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.30 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.30 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.30 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31205461 | 0.80 | GAA (0.32) | ALDH1A1GAAKDM4EMAPK1SMN1; SMN2 | |
| SCHEMBL29548353 | 0.79 | NQO2 (0.37) | ALDH1A1GAAKDM4EMAPK1SMN1; SMN2 | |
| SCHEMBL31205096 | 0.79 | GAA (0.41) | ALDH1A1GAAKDM4EMAPK1SMN1; SMN2 | |
| SCHEMBL31205450 | 0.76 | FNTA (0.37) | ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL17847672 | 0.75 | MAP4K4 (0.38) | MAP4K4DYRK1AGAAKDM4ESMPD3 | |
| SCHEMBL31205416 | 0.75 | KDM4E (0.33) | ALDH1A1KDM4EMAPK1SMN1; SMN2 | |
| SCHEMBL31205602 | 0.75 | CA1 (0.44) | ALDH1A1GAATUBB1 | |
| SCHEMBL31205538 | 0.75 | ADRA1A (0.37) | ALDH1A1KDM4E | |
| SCHEMBL25759425 | 0.74 | MAP4K4 (0.33) | MAP4K4GAA | |
| SCHEMBL31205486 | 0.73 | TDP1 (0.38) | ALDH1A1TDP1GAAKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727935-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. (CN) | 2026-04-22 | — | — | EP | disclosed |
| WO-2025111547-A1 | 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF | RGENTA THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| WO-2024254832-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024255886-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-12-19 | — | — | WO | disclosed |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-10-29 | — | — | US | disclosed |
| EP-4448514-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. (CN) | 2024-10-23 | — | — | EP | disclosed |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| WO-2023109954-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023109954-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2017081003-A1 | SUBSTITUTED PYRAZOLOPYRIDINAMINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | MAP4K4 245/4885DYRK1A 56/4885ALDH1A1 4805/4885 |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | MAP4K4 245/4885DYRK1A 56/4885ALDH1A1 4805/4885 |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | TYK2, JAK2, JAK1 | MAP4K4 245/4885DYRK1A 56/4885ALDH1A1 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.